IMMUNOCORE HLDGS ADS/1 - Asset Resilience Ratio

Latest as of December 2025: 37.15%

IMMUNOCORE HLDGS ADS/1 (6YG) has an Asset Resilience Ratio of 37.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of IMMUNOCORE HLDGS ADS/1 for a breakdown of total debt and financial obligations.

Liquid Assets

€396.44 Million

≈ $463.48 Million USD Cash + Short-term Investments

Total Assets

€1.07 Billion

≈ $1.25 Billion USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2023–2025)

This chart shows how IMMUNOCORE HLDGS ADS/1's Asset Resilience Ratio has changed over time. See IMMUNOCORE HLDGS ADS/1 shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down IMMUNOCORE HLDGS ADS/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IMMUNOCORE HLDGS ADS/1 (6YG) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€396.44 Million	37.15%
Total Liquid Assets	€396.44 Million	37.15%

Asset Resilience Insights

Very High Liquidity: IMMUNOCORE HLDGS ADS/1 maintains exceptional liquid asset reserves at 37.15% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

IMMUNOCORE HLDGS ADS/1 Industry Peers by Asset Resilience Ratio

Compare IMMUNOCORE HLDGS ADS/1's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for IMMUNOCORE HLDGS ADS/1 (2023–2025)

The table below shows the annual Asset Resilience Ratio data for IMMUNOCORE HLDGS ADS/1.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	37.15%	€396.44 Million ≈ $463.48 Million	€1.07 Billion ≈ $1.25 Billion	+1.02pp
2024-12-31	36.12%	€364.64 Million ≈ $426.31 Million	€1.01 Billion ≈ $1.18 Billion	--
2023-12-31	0.00%	€0.00 ≈ $0.00	€597.00 Million ≈ $697.96 Million	--

pp = percentage points

About IMMUNOCORE HLDGS ADS/1

F:6YG Germany Biotechnology

Market Cap

$1.47 Billion

€1.26 Billion EUR

Market Cap Rank

#7782 Global

#1047 in Germany

Share Price

€24.80

Change (1 day)

-1.59%

52-Week Range

€24.60 - €34.60

All Time High

€69.50